中华皮肤科杂志
中華皮膚科雜誌
중화피부과잡지
Chinese Journal of Dermatology
2011年
1期
11-14
,共4页
银屑病%CD4阳性T淋巴细胞%白细胞介素17%白细胞介素22
銀屑病%CD4暘性T淋巴細胞%白細胞介素17%白細胞介素22
은설병%CD4양성T림파세포%백세포개소17%백세포개소22
Psoriasis%CD4-positive T-lymphocytes%Interleukin-17%Interleukin-22
目的 探讨寻常性银屑病患者外周血和皮损中Th17细胞及相关因子IL-17、IL-22表达,分析其与疾病严重程度及病程的相关性.方法 抽取44例寻常性银屑病患者和28例正常人对照者外周血,用三色法流式细胞仪检测外周血n17细胞,ELISA法检测血清中IL-17、IL-22表达.取20例寻常性银屑病患者皮损和8例正常人对照者皮肤,用量子点免疫荧光双标法检测Th17细胞表达.结果 寻常性银屑病患者外周血Th17细胞百分比(4.71%±2.55%)高于正常人对照组(0.55%±0.39%),两组差异有统计学意义(P＜0.01).银屑病患者Th17细胞与银屑病病情严重度评分(PASI)呈显著正相关(r=0.53,P＜0.01),但与病程无相关性(r=0.09,P＞0.05).银屑病患者血清中IL-17(24.02±12.31 ng/L)、IL-22(18.32±8.14 ng/L)表达均高于正常人对照组(IL-17为7.16±4.04 ng/L,IL-22为6.52±4.15 ng/L),差异均有统计学意义(P＜0.01和＜0.05).银屑病患者血清IL-17、IL22表达与PASI呈显著正相关(r=0.47,P＜0.01;r=0.53,P＜0.01),与病程无相关性(r=0.03,P＞0.05;r=0.19,P＞0.05).银屑病患者皮损中可见Th17细胞浸润,主要集中在真皮浅层血管周围;而正常人皮肤中仅有微量CD4+T细胞表达,未见Th17细胞.结论 Th17细胞参与银屑病的发病,提示阻断相关因子IL-17、IL-22的药物可成为治疗银屑病的又一新靶点.
目的 探討尋常性銀屑病患者外週血和皮損中Th17細胞及相關因子IL-17、IL-22錶達,分析其與疾病嚴重程度及病程的相關性.方法 抽取44例尋常性銀屑病患者和28例正常人對照者外週血,用三色法流式細胞儀檢測外週血n17細胞,ELISA法檢測血清中IL-17、IL-22錶達.取20例尋常性銀屑病患者皮損和8例正常人對照者皮膚,用量子點免疫熒光雙標法檢測Th17細胞錶達.結果 尋常性銀屑病患者外週血Th17細胞百分比(4.71%±2.55%)高于正常人對照組(0.55%±0.39%),兩組差異有統計學意義(P＜0.01).銀屑病患者Th17細胞與銀屑病病情嚴重度評分(PASI)呈顯著正相關(r=0.53,P＜0.01),但與病程無相關性(r=0.09,P＞0.05).銀屑病患者血清中IL-17(24.02±12.31 ng/L)、IL-22(18.32±8.14 ng/L)錶達均高于正常人對照組(IL-17為7.16±4.04 ng/L,IL-22為6.52±4.15 ng/L),差異均有統計學意義(P＜0.01和＜0.05).銀屑病患者血清IL-17、IL22錶達與PASI呈顯著正相關(r=0.47,P＜0.01;r=0.53,P＜0.01),與病程無相關性(r=0.03,P＞0.05;r=0.19,P＞0.05).銀屑病患者皮損中可見Th17細胞浸潤,主要集中在真皮淺層血管週圍;而正常人皮膚中僅有微量CD4+T細胞錶達,未見Th17細胞.結論 Th17細胞參與銀屑病的髮病,提示阻斷相關因子IL-17、IL-22的藥物可成為治療銀屑病的又一新靶點.
목적 탐토심상성은설병환자외주혈화피손중Th17세포급상관인자IL-17、IL-22표체,분석기여질병엄중정도급병정적상관성.방법 추취44례심상성은설병환자화28례정상인대조자외주혈,용삼색법류식세포의검측외주혈n17세포,ELISA법검측혈청중IL-17、IL-22표체.취20례심상성은설병환자피손화8례정상인대조자피부,용양자점면역형광쌍표법검측Th17세포표체.결과 심상성은설병환자외주혈Th17세포백분비(4.71%±2.55%)고우정상인대조조(0.55%±0.39%),량조차이유통계학의의(P＜0.01).은설병환자Th17세포여은설병병정엄중도평분(PASI)정현저정상관(r=0.53,P＜0.01),단여병정무상관성(r=0.09,P＞0.05).은설병환자혈청중IL-17(24.02±12.31 ng/L)、IL-22(18.32±8.14 ng/L)표체균고우정상인대조조(IL-17위7.16±4.04 ng/L,IL-22위6.52±4.15 ng/L),차이균유통계학의의(P＜0.01화＜0.05).은설병환자혈청IL-17、IL22표체여PASI정현저정상관(r=0.47,P＜0.01;r=0.53,P＜0.01),여병정무상관성(r=0.03,P＞0.05;r=0.19,P＞0.05).은설병환자피손중가견Th17세포침윤,주요집중재진피천층혈관주위;이정상인피부중부유미량CD4+T세포표체,미견Th17세포.결론 Th17세포삼여은설병적발병,제시조단상관인자IL-17、IL-22적약물가성위치료은설병적우일신파점.
Objective To detect the quantity of Th17 cells and expressions of related cytokines including interleukin (IL)-17 and IL-22, in peripheral blood and skin lesions of patients with psoriasis vulgaris, and to analyze their correlation with disease severity and clinical course. Methods Peripheral blood was obtained from 44 patients with progressive psoriasis vulgaris and 28 normal human controls. Three-color flow cytometry was carried out to detect the quantity of Th17 cells, and ELISA to examine the levels of serum IL-17 and -22.Skin samples were obtained from 20 patients with psoriasis vulgaris and 8 normal human controls, and a quantum dot-based double labled immumofluorescence method was used to determine the quantity of Th17 cells.Results The percentage of peripheral blood Th17 cells was higher in patients with psoriasis vulgaris than in normal human controls (4.71% ± 2.55% vs. 0.55% ± 0.39%, P ＜ 0.01 ). Elevated expressions of IL-17 and IL-22 were noted in the patients compared with the normal human controls (24.02 ± 12.31 ng/L vs. 7.16 ±4.04 ng/L, P ＜ 0.05; 18.32 ± 8.14 ng/L vs. 6.52 ± 4.15 ng/L, P ＜ 0.01 ). The percentage of peripheral blood Th17 cells and serum levels of IL-17 and IL-22 were positively correlated with psoriasis area and severity index (r= 0.53, 0.47, 0.53, respectively, all P ＜ 0.01 ), but unrelated to the clinical course of psoriasis (r = 0.09,0.03, 0.19, respectively, all P ＞ 0.05). There was an infiltrate of Th17 cells in psoriatic lesions, which was mainly distributed around the blood vessels in superficial dermis, whereas there were only a small number of CD4+ T cells in the normal control skin with the absence of Th17 cells. Conclusions Th17 cells are involved in the development of psoriasis, and Th17 cell-secreted cytokines, such as IL-17 and IL-22, may serve as a new therapeutic target for psoriasis.
